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MCF-7Nonsteroidal anti-inﬂammatory drugs (NSAIDs) have been considered for use in the prevention and
treatment of cancer malignancy. FR122047 (FR) is known to have an anti-inﬂammatory effect, but the
anticancer activity of the chemical has not yet been identiﬁed. In the present study, we could ﬁnd that
treatment of breast cancer MCF-7 cells with FR led to apoptosis accompanying with apparent activation of
caspases. Treatment of caspase-speciﬁc inhibitors revealed that FR-induced apoptosis was caspase-8-
dependent and inhibition of caspase-9 activity resulted in unexpected, marked enhancement of cell death.
Knockdown of caspase-9 expression by speciﬁc siRNA caused increased susceptibility to FR-induced cell
death, consistent with the results obtained with treatment of caspase-9 inhibitor. Inhibition of caspase-9
blocked the autophagic process by modulating lysosomal pH and acid-dependent cathepsin activities and
augmented cell death due to blockage of cytoprotective autophagy. MCF-7 cells treated with sulforaphane, an
autophagy-inducing drug, also showed marked accumulation of LC3-II, and co-treatment with caspase-9
inhibitor brought about increased susceptibility to sulforaphane-induced cell death. Different from the cases
with FR or sulforaphane, etoposide- or doxorubicin-induced cell death was suppressed with co-treatment of
caspase-9 inhibitor, and the drugs failed to induce signiﬁcant autophagy in MCF-7 cells. Taken together, our
data originally suggest that inhibition of caspase-9 may block the autophagic ﬂux and enhance cell death due
to blockage of cytoprotective autophagy.technolgy, Konkuk University,
2 455 1044.
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Breast cancer is one of the most common malignancies in women
globally and the second leading cause of cancer mortality in females.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs), which inhibit the
enzyme cyclooxygenase (COX), have been considered for use in the
prevention and treatment of malignancy [1–4]. Epidemiological
studies have reported that long-term use of NSAIDs reduces the risk
of cancer of the breast, prostate, colon, lung, and other gastrointestinal
organs [5–10]. However, the molecular mechanisms underlying
NSAID-induced apoptosis in breast cancer are poorly understood.
FR122047, a selective and potent inhibitor of COX-1, is known to have
an anti-inﬂammatory effect in animal models of chronic inﬂammation
[11,12], but the anticancer activity of the chemical has not yet been
identiﬁed.
Apoptosis is a well-characterized process of non-necrotic cell death,
which is triggered by activation of both the mitochondrial (intrinsic)
and death receptor (extrinsic) pathways [13]. Although apoptotic cell
death is generally known to require caspase activity and can besuppressed by speciﬁc caspase inhibitors, recent evidence suggests that
caspase inhibitors can also promote necrotic cell death and enhance
even stress-induced apoptosis [14,15]. A comprehensive analysis of the
functionsof caspases, extendingbeyond theﬁndings of previous studies,
remains to be done.
In recent years, autophagy has been shown to induce caspase-
independent cell deathwithout themorphological changes characteristic
of apoptosis, such as membrane blebbing, cell shrinkage, and chromatin
condensation [16]. Autophagy is an evolutionarily conservedmechanism
by which long-lived proteins and damaged organelles are digested in
lysosomes [17,18]. Autophagy also promotes cancer cell survival under
conditions of stress, such as starvation, and functions as a defense
mechanism in response to various anticancer agents [19,20]. Despite of a
lot of studies on the relationship between autophagy and apoptosis, the
functional relationship between caspases and autophagy is not well
understood.
Here, we report that treatment ofMCF-7 breast cancer cells with the
NSAID FR122047 (FR) leads to the activation of a linear cascade of
caspases. We originally found that inhibition of caspase-9 may
unpredictably enhance cell death due to blockage of cytoprotective
autophagy. Our data provide new insights into the understanding of the
relationship between caspases and cytoprotective autophagy and
suggest the possibility that caspase-9 may be involved in the
cytoprotective autophagic process.
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2.1. Reagents
FR122047, a nonsteroidal anti-inﬂammatory drug (NSAID), baﬁlo-
mycin A1, pepstatin A methyl ester, and E-64D were purchased from
Calbiochem (La Jolla, CA, USA) and dissolved in dimethyl sulfoxide
(DMSO) and 3,3′dihexyloxacarbocyanine iodide (DiOC6(3)), were from
Molecular Probes (Eugene, OR, USA). Electrophoresis reagents and Bio-
Rad protein assay kit were obtained from Bio-Rad (Hercules, CA, USA).
Rapamycin, chloroquine, etoposide, doxorubicin, and carbonyl cyanide
m-chlorophenylhydrazone (CCCP) were purchased from Sigma Chem-
ical Co. (St. Louis,MO,USA). Pancaspase inhibitor (z-VAD-FMK), caspase-
8 inhibitor (z-IETD-FMK), and caspase-9 inhibitor (z-LEHD-FMK) were
fromBDBiosciences (SanDiego, CA,USA). D,L-Sulforaphane(purityN99%)
was from LKT Laboratories (St. Paul, MN, USA).2.2. Cell culture and transfection
MCF-7 breast cancer cells were cultured in DMEM supplemented
with 10% heat-inactivated fetal bovine serum and 100 U/ml penicillin/
streptomycin (Life Technologies, Inc., Gaithersburg, MD, USA). Plasmid
GFP-LC3 was kindly provided by Dr. Tamotsu Yoshimori (Research
Institute for Microbial Diseases, Osaka University, Japan). The transfec-
tion was carried out using Lipofectamine (Invitrogen, Paisley, UK)
according to the manufacturer's protocol, and stable cell lines were
selected by growth in presence of 800 μg/ml G418. MCF-7 cells
expressing GFP-tagged LC3 were used to demonstrate induction of
autophagy. To produce Bcl-2-overexpressing MCF-7 cells, cells were
transfected with pcDNA-Bcl-2 using Lipofectamine 2000 and stable cell
lines were selected by growth in the presence of G418. Cells were
maintained under a humidiﬁed atmosphere of 95% air 5% CO2 at 37 °C.2.3. DAPI staining
DAPI (4′,6-diamidino-2-phenylindole ) staining of DNA was per-
formed as described previously [42]. Brieﬂy, cells were ﬁxed in ice-cold
methanol/acetone (1:1; v/v) for 15 min and then stainedwith theDNA-
speciﬁc ﬂuorochrome DAPI in the dark. Morphological changes in the
apoptotic cells were observed and photographed using a Zeiss Axiovert
200 microscope. Apoptotic cells were identiﬁed by condensation and
nuclear fragmentation, and the percentage of apoptotic cells was
calculated as the ratio of apoptotic cells to total cells counted.2.4. Flow cytometry analysis
For detection of sub-diploid population, cells were detached from
plates by the addition of 0.25% trypsin–EDTA, washed in phosphate-
buffered saline (PBS), ﬁxed in 70% ethanol, and stained with
propidium iodide (PI) for 15 min at room temperature in the dark.
Analysis of cells with sub-G0/G1 DNA content (subdiploid cells) was
performed on 10,000 cells on a FACScan ﬂow cytometer using the
CellQuest analysis program (Becton-Dickinson, Cowley, UK), as
described previously [43]. PI-exclusion assay was used to determine
the percentage of viable cells. Brieﬂy, after treatment, cells were
collected, incubated for 10 min on ice in the dark in PBS containing
20 μg/ml PI, and then analyzed with FACScan ﬂow cytometer. For
determination of mitochondrial membrane potential, cells were
collected after exposure to 30 μM FR122047 for 24 h. Cells were
washed and resuspended in 1 ml of PBS containing 2 μM DiOC6(3),
incubated at 37 °C in the dark for 15 min, and then washed and
resuspended in PBS. Mitochondrial membrane potential (Δψm) was
assessed by ﬂow cytometry [44].2.5. Preparation of mitochondrial and cytoplasmic fractions
After the indicated treatments, cellswerewashed three times in cold
PBS and scraped from the dishes. Mitochondrial and cytoplasmic
fractions were prepared using a mitochondrial fractionation kit (Active
Motif, CA, USA), according to the manufacturer's protocol.
2.6. Western blot analysis
To prepare whole-cell extracts, cells were washed three times in
cold PBS, scraped from the dishes, and suspended in extraction buffer
(1% Triton X-100, 100 mMTris–HCl, pH 8.8, 10 mMNaCl, 10% glycerol,
1 mM sodium orthovanadate, 50 mM sodium ﬂuoride, 1 mM p-
nitrophenyl phosphate, and 1 mM phenylmethylsulfonyl ﬂuoride).
After incubation on ice for 30 min, lysates were centrifuged and
proteins in the supernatants were quantiﬁed using the Bradford
Protein Assay Reagent (Bio-Rad). An equal amount of proteins was
then separated on a 10–15% SDS-PAGE gel followed by electrophoretic
transfer to nitrocellulose membranes. Membranes were blocked in 5%
nonfat dry milk and 0.1% Tween-20 in Tris-buffered saline and probed
with primary antibody. Antibodies against caspase-7, actin, Bcl-2, Bcl-
xL, Bax, VDAC, cytochrome c, and cleaved poly (ADP-ribose)
polymerase (PARP) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies against TRADD, Bid, caspase-8, and
caspase-9 were from Cell Signaling (Beverly, MA, USA). LC3 antibody
was purchased from Novus Biologicals (Littleton, CO, USA). Antibody–
antigen complexes were incubated with goat anti-mouse IgG- or goat
anti-rabbit IgG-peroxidase conjugates, followed by detection using an
enhanced chemiluminescence (ECL) kit (Amersham Biosciences,
Uppsala, Sweden).
2.7. RT-PCR analysis
Total RNA was extracted from the cells using Trizol reagent (Gibco
BRL) according to the manufacturer's protocol, and the extracted RNA
samples were subsequently treated with MMLV reverse transcriptase
(Promega). PCRs were performed using speciﬁc primers for LC3B:
forward, 5′-CGGAGAAGACCTTCAAGCAG-3′ and reverse, 5′-
CTGGGAGGCATAGACCATGT-3′; ATG7: forward, 5′-ACCCAGAA-
GAAGCTGAACGA-3′ and reverse, 5′-AGACAGAGGGCAGGATAGCA-3′;
and GAPDH: forward, 5′-GGGAAGAGTCAACGGATTTGGTCGT-3′ and
reverse, 5′-GGGAATTGATTTTGGAGGGATCTCG-3′. The cycling condi-
tions were 94 °C for 5 min, followed by 35 cycles at 94 °C for 30 s, at
58 °C for 30 s, and at 72 °C for 1 min and a ﬁnal extension at 72 °C for
10 min. The PCR products were analyzed by electrophoresis on 1%
agarose gel containing ethidium bromide and photographed under
ultraviolet light.
2.8. Fluorescence microscopy
Cellswere treatedwith30 μMFR122047 for 24 h and incubatedwith
50 μM MDC, a selective ﬂuorescent marker for autophagic vacuoles, at
37 °C for 60 min as described previously [26]. The cells were examined
under a ﬂuorescence microscope (Carl Zeiss). To detect acidic vesicular
organelles (AVOs), cells were stained with 5 μg/ml acridine orange for
15 min andwashedwith PBS. Formation of AVOswas examined under a
ﬂuorescencemicroscope. For LysoTracker staining, cells were incubated
for 30 min in PBS with 75 nM LysoTracker Red (Lonza, PA-3015) and
observed under a confocal microscope (Olympus).
2.9. Assay for caspase-9 or cathepsin B activity
After the indicated treatments, cells were collected and lysed on
ice for 10 min. Caspase-9 activity was measured using a colorimetric
assay kit (Calbiochem, La Jolla, CA, USA) and LEDH-pNA as substrate.
The amount of free pNA was determined by measuring absorbance at
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assay kit (Calbiochem, La Jolla, CA, USA) and z-Arg-Arg-AMC as
substrate. Activity was determined by measuring ﬂuorescence of free
AMC on a ﬂuorescence plate reader at an excitation wavelength of
370 nm and emission wavelength of 450 nm.Fig. 1. Treatment of breast cancer MCF-7 cells with FR122047 induces apoptosis and caspase
(0 μM) for 24 h, ﬁxed, and stained with DAPI. Images were acquired using a ﬂuorescence mi
apoptotic cells to total cells. Values represent the mean±SE from three independent experim
FR for 24 h and lysed, and proteins were separated by SDS-polyacrylamide gel electrophore
(loading control), and proteins were visualized using the ECL detection system. Representati
cells was determined by ﬂow cytometry after treatment with 30 μM FR or DMSO alone for 2
were analyzed by Western blotting with antibodies to caspase-8, caspase-7, caspase-9, and
presented. (E) Cells were incubated with 30 μM FR for the indicated time period. The express
loading control. Representative blots from three independent experiments were shown. (F
24 h, and caspase-9 activation was analyzed by Western blotting with anti-caspase-9 antibo
cells were cultured in 30 μM FR or 50 μM carbonyl cyanidem-chloro-phenylhydrazone (CCC
potential (ΔΨm) was analyzed by FACScan. Values represent the mean±SE from three indep
30 μM FR for 24 h, an accumulation of cytochrome c (Cyto c) in the cytoplasmic fraction was
three independent experiments were shown. (I) Cells were treated with 30 μM FR for 24
cleavage assay and LEHD-pNA as substrate. Values represent the mean±SE from three ind2.10. Transmission electron microscopy
Cells were ﬁxed with 2.5% glutaraldehyde in 0.1 M PBS, pH 7.4, for
2 h and thenwashed three times in 0.1 M PBS. Cells were post-ﬁxed in
2 mM osmium tetroxide in 0.1 M PBS for 1 h, dehydrated in anactivation. (A) Cells were treated with 10, 20, or 30 μM FR122047 (FR) or DMSO alone
croscope. Cells were counted and percentage of apoptotic cells expressed as the ratio of
ents. *Pb0.05 versus the control (DMSO). (B) Cells were treated with 0, 10, 20, or 30 μM
sis. Western blot analysis was performed using antibody against cleaved PARP or actins
ve blots from three independent experiments were shown. (C) Percentage of subdiploid
4 h. (D) Cells were treated with 30 μM FR for the indicated time period, and cell lysates
actin (loading control). Representative data from three independent experiments were
ion of Bid, Bcl-2, Bcl-xL, or Bax was analyzed byWestern blotting, and actin was used as
) Control MCF-7 and Bcl-2-overexpressing MCF-7 cells were treated with 30 μM FR for
dy. Representative blots from three independent experiments were shown. (G) MCF-7
P; positive control) for 24 h, stained with 2 μMDiOC6(3), and mitochondrial membrane
endent experiments. *Pb0.05 versus the control (DMSO). (H) Following treatment with
accessed byWestern blotting with antibody to cytochrome c. Representative blots from
h, and the level of caspase-9 activity in cell lysates was analyzed using a colorimetric
ependent experiments. *Pb0.05 versus the control (DMSO).
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EMbed 812 kit (Electron Microscopy Sciences, Hatﬁeld, PA, USA).
Sections of 70 nm were double-stained with 3% uranyl acetate and
lead citrate and examined using a transmission electron microscope
(H-7600s, Hitachi, Japan) at an acceleration voltage of 80 kV.
2.11. Knockdown of caspase-9 expression by small interfering RNA
Cells were seeded in 60-mm dishes and incubated for 24 h. The
next day, cells were transfected with human caspase-9 siRNA directed
against caspase-9 (siGENOME SMART pool reagents, Dharmacon,Fig. 2. Blockageof caspase-9 function signiﬁcantly enhances FR122047-induced cell death. (A)M
(z-VAD), caspase-8 inhibitor z-IETD-FMK(Cas8-inh), or caspase-9 inhibitor z-LEHD-FMK(Cas9-
analyzed by FACScan. Values represent themean±SE from three independent experiments. *Pb
20 μM caspase-9 inhibitor z-LEHD-FMK (Cas9-inh) for 24 h, and cell viability was determined b
independent experimentswerepresented. (C) Cellswerepreincubatedwith 20 μMcaspase- 9 in
blot analyses were conducted with antibodies to caspase-8, caspase-7, cleaved PARP, and acti
densitometric analysesof cleaved caspase-8, cleaved caspase-7, and cleavedPARP levels. (E) Cell
by addition of 100 μM sulforaphane (SFN), 400 μM etoposide (Etopo), or 10 μM doxorubicin (D
represent the mean±SE from three independent experiments. *Pb0.05 versus the drug aloneLafayette, CO, USA) using LipofectAMINE 2000 reagent (Invitrogen,
Paisley, UK) according to the manufacturer's protocol. A control siRNA
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as negative
control. Knockdown of caspase-9 expression by siRNA was assessed
by Western blot analysis.2.12. Statistical analysis
The Student's t-test was used for testing statistical signiﬁcance
between groups and Pb0.05 was considered signiﬁcant.CF-7 cellswere incubated in the presence or absenceof pan-caspase inhibitor z-VAD-FMK
inh) for 1 h before the addition of 30 μMFR. Cellswere incubated for another 24 h and then
0.05 versus FR alone. (B) Cells were incubated in the presence or absence of 30 μMFR and
y PI-exclusion assay. The gated cells represent viable cells. Representative data from three
hibitor, z-LEHD-FMK(Cas9-inh) for 1 hprior to treatmentwith 30 μMFR for 24 h.Western
n. Representative blots from three independent experiments were shown. (D) Results of
swerepretreatedwith20 μMcaspase-9 inhibitor, z-LEHD-FMK(Cas9-inh) for 1 h followed
oxo) and incubated for another 24 h. Subdiploid cells were analyzed by FACScan. Values
.
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3.1. Treatment with the NSAID FR122047 promotes apoptosis and
caspase activation in MCF-7 cells
To determine whether the NSAID FR122047 (FR) induces apoptotic
cell death in MCF-7 cells, we examined changes in nuclear morphology
in FR-treated cells by DAPI staining. Treatment with FR resulted in
pronounced apoptotic chromatin condensation and a signiﬁcant
increase in the percentage of apoptotic cells (Fig. 1A).We also examined
changes in PARP cleavage as a marker for apoptosis and the proportion
of apoptotic cells with subdiploid DNA content. FR treatment elicited an
increase in PARP cleavage (Fig. 1B) and apparent enhancement in the
proportion of apoptotic cells with subdiploid DNA content (Fig. 1C).
Moreover, time-dependent increases in caspase-8, caspase-7, and
caspase-9 cleavages were detected in caspase-3-deﬁcient MCF-7 cells
following FR treatment [21] (Fig. 1D). Treatment of FR also induced the
expression of FADD (Fas-associated death domain protein) and TRADD
(TNFR-1-associated death domain protein), components of DISC
(death-inducing signaling complex) in MCF-7 cells (Fig. S1). To
investigate whether FR treatment would trigger the recruitment ofFig. 3. FR122047 treatment induces autophagy in MCF-7 cells. (A) MCF-7 cells were treate
electron microscopy. Arrows and arrowheads indicate autophagosomes and autophagolysos
were treated with 30 μM FR for the indicated times, and cell lysates were analyzed by West
three independent experiments were shown. (C) Cells were treated with 30 μM FR for the ind
levels relative to GAPDH are presented. The experiments were repeated independently at lea
DMSO alone and examined by confocal microscopy. Nuclei were stained with TOPRO-3 (
independent experiments. (E) Cells were treated with 30 μM FR or DMSO alone for 24 h an
represent 20 μm. Right, enlarged images of areas indicated by squares. Images representative
30 μM FR or DMSO alone for 24 h, and formation of AVOs (red ﬂuorescence) was examinedcaspase-8 into FADD in FR122047-treated MCF-7 cells, lysates from FR-
treated MCF-7 cells were immunoprecipitated with anti-FADD anti-
body. The results from immunoprecipitation experiments showed
obvious direct association between FADD and caspase-8 in FR-treated
MCF-7 cells, indicating that caspase-8 activation correlates with
components of DISC (Fig. S2). Next, we analyzed the expression level
of theBcl-2 family proteins in FR-treatedMCF-7 cells. TreatmentofMCF-
7 cells with FR resulted in induction of Bid cleavage into truncated form
(tBid) and down-regulation of Bcl-2 expression with no change in
expression of Bcl-xL or Bax, leading to an increase in the Bax/Bcl-2 ratio
(Fig. 1E). We could conﬁrm that overexpression of Bcl-2 exhibited the
inhibition of FR-induced caspase-9 activation (Fig. 1F). In addition,
treatmentwith FR induced analteration of themitochondrialmembrane
potential (ΔΨm) of MCF-7 cells as detected with theΔΨm—sensitive dye
DiOC6(3) (Fig. 1G). As this event results in accumulation of cytochrome c
in the cytosol and a subsequent activation of caspase-9 [22], we
investigated effect of FR on cytochrome c release andanalyzed caspase-9
activity by assaying cleavage of the substrate LEHD-pNA in lysates of FR-
treated cells. We could ﬁnd that treatment of MCF-7 cells with FR
triggered signiﬁcant release ofmitochondrial cytochrome c (Fig. 1H) and
caspase-9 activation (Fig. 1I).d with 30 μM FR122047 (FR) or DMSO alone for 18 h and processed for transmission
omes, respectively. Scale bars represent 2 μm (8000×) and 500 nm (12,000×). (B) Cells
ern blotting for levels of LC3-I (18 kDa) and LC3-II (16 kDa). Representative blots from
icated times, and the mRNA level of LC3B or ATG 7 was analyzed by RT-PCR. Expression
st three times. (D) Cells transfected with GFP-LC3were treated for 24 hwith 30 μMFR or
blue). Scale bars represent 20 μm. Images were representative of the results of three
d labeled with MDC. Images were acquired using ﬂuorescence microscopy. Scale bars
of the results of three different experiments were presented. (F) Cells were treated with
under a ﬂuorescence microscope.
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FR122047-induced cell death
Next, we examined whether the caspase inhibitors would suppress
FR-induced cell death inMCF-7 cells. Additionof thepan-caspase inhibitor
z-VAD-FMK or the caspase-8 inhibitor z-IETD-FMK signiﬁcantly blocked
the accumulation of a subdiploid fraction in FR-treated cells (Fig. 2A).Fig. 4. Treatment with caspase-9 inhibitor suppresses FR122047-induced autophagy. (A) Cell
the addition of 30 μMFR122047 (FR). The cells were incubated for another 24 h and then ana
*Pb0.05 versus FR alone. Bottom panel: cells were preincubated with 20 nM rapamycin (
conducted with antibodies to LC3 and actin. (B) Cells were pretreated with 20 μM chloroquin
of 30 μM FR. Cells were incubated for another 24 h, and cell lysates were analyzed by Wes
presented. (C) Cells were pretreated with 100 nM baﬁlomycin A1 or cathepsin inhibitors (E
30 μM FR. Cells were incubated for another 24 h, and cell lysates were analyzed byWestern b
20 μM caspase-9 inhibitor, z-LEHD-FMK (Cas9-inh), or 100 nM baﬁlomycin A1 for 1 h before
(red ﬂuorescence) was examined under a ﬂuorescencemicroscope. (E) Cathepsin B activity a
20 μM chloroquine or 20 μM caspase-9 inhibitor. Values represent the mean±SE of from th
alone. (F) GFP-LC3-expressing cells were pretreated with 20 μMcaspase-9 inhibitor, z-LEHD-
24 h, stained with Lysotracker Red dye (Lysotracker), and observed under a confocal microUnpredictably, co-treatment with the caspase-9 inhibitor, z-LEHD-FMK,
however, resulted in a marked increase in cell death (Fig. 2A) and a
signiﬁcant reduction in cell viability compared to FR alone (Fig. 2B).
Addition of the caspase-9 inhibitor showed inhibition of caspase-7 and
PARP cleavages but did not affect caspase-8 cleavage in FR-treatedMCF-7
cells (Fig. 2C and D), suggesting that caspase-9-mediated alternative
pathway may be involved in regulation of FR-induced cell death in thes were pretreated with 20 nM rapamycin (RA) or 20 μM chloroquine (CQ) for 1 h before
lyzed by FACScan. Values represent themean±SE from three independent experiments.
RA) for 1 h prior to treatment with 30 μM FR for 24 h and Western blot analysis was
e (CQ) or 20 μM caspase-9 inhibitor, z-LEHD-FMK (Cas9-inh) for 1 h before the addition
tern blotting. Images representative of the results of three different experiments were
64d+Pepstatin A methyl ester (E/P), 10 μg/ml for each) for 1 h before the addition of
lotting. (D) Cells were pretreated with 20 μM chloroquine (CQ), 20 nM rapamycin (RA),
the addition of 30 μM FR. Cells were incubated for another 24 h, and formation of AVOs
ssay was performed after treatment for 12 hwith 30 μMFR alone or in combination with
ree independent experiments. *Pb0.05 versus the control (DMSO), **Pb0.01 versus FR
FMK (Cas9-inh) for 1 h before the addition of 30 μMFR. Cells were incubated for another
scope. Scale bars represent 50 μm.
Fig. 4 (continued).
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by caspase-9 inhibitor occurs only in concert with the action of FR. MCF-7
cells were treated with sulforaphane, etoposide, or doxorubicin, in the
presence andabsence of caspase-9 inhibitor. Co-treatmentwith caspase-9
inhibitor resulted in increased susceptibility to sulforaphane-induced cell
death, consistentwith the results obtainedwith FR. Distinct from its effect
with FR or sulforaphane, co-treatment of caspase-9 inhibitor led to a
decrease in etoposide- or doxorubicin-induced cell death of MCF-7 cells
(Fig. 2E).3.3. FR treatment leads to induction of autophagy in MCF-7 cells
As sulforaphane has been reported to induce autophagy [23], we
investigated whether autophagy, which corresponds to type II
programmed cell death, occurs in FR-treated MCF-7 cells. Transmis-
sion electron microscopy revealed a pronounced increase in the
autophagic compartments in FR-treated cells (Fig. 3A). Moreover,
there was a time-dependent increase in the level of LC3-II in FR-
treated MCF-7 cells (Fig. 3B), although there was no apparent time-
dependent change in the mRNA level of LC3 (Fig. 3C). We could also
detect a signiﬁcant time-dependent increase in themRNA level of ATG
7 in FR-treated cells (Fig. 3C). Previous studies have reported that the
LC3-II form is primarily localized to autophagosomal membranes [24].
As expected, ﬂuorescence microscopic analysis showed that, in GFP-
LC3-expressing MCF-7 cells, GFP was distributed in a punctuate
pattern after FR treatment, indicating translocation of LC3-II to
autophagosomes (Fig. 3D). In contrast, GFP-LC3 ﬂuorescence
appeared in a diffuse cytoplasmic pattern in DMSO-treated control
MCF-7 cells. When cells were stained with monodansylcadaverine
(MDC), a spontaneously ﬂuorescent dye that selectively labels
autophagosomes and autolysosomes [25,26], FR-treated MCF-7 cells
exhibited strong staining compared to DMSO-treated cells (Fig. 3E).
As formation of acidic vesicular organelles (AVOs) correlates with
autophagy [23], we could also conﬁrm that treatment of FR resulted in
apparent formation of AVOs (red ﬂuorescence) in MCF-7 cells
(Fig. 3F). These ﬁndings apparently reveal that autophagy is induced
in the response of MCF-7 cells to FR treatment.3.4. Co-treatment with caspase-9 inhibitor results in suppression of
FR-induced autophagy
Next, we investigated whether FR-induced autophagy is involved
in cell death or in cell survival. Treatment of rapamycin, a speciﬁc
mTOR inhibitor that promotes autophagy [27,28], led to protection of
FR-induced cell death (Fig. 4A). The elicitation of autophagy by
rapamycin treatment was conﬁrmed by the conversion of LC3-I to
LC3-II (Fig. 4A, bottom panel). In contrast, treatment of chloroquine, a
lysosomal enzyme inhibitor [19,29], markedly enhanced FR-induced
cell death (Fig. 4A), implying that autophagywould play a defensive role
in FR-induced cell death. Since chloroquine is known to be a lysosomal
enzyme inhibitor [19,29] and blocks the lysosomal degradation of
autophagosomes [30], we assessed the effect of chloroquine on FR-
induced LC3-II accumulation. Chloroquine alone induced an increase in
the level of LC3-II and had an additive effect on FR-induced
accumulation of LC3-II in MCF-7 cells (Fig. 4B). Interestingly, treatment
with caspase-9 inhibitor also showed an increase of both LC3-I and LC3-
II levels in FR-treated MCF-7 cells (Fig. 4B). Treatment with another
autophagy inhibitor, such as baﬁlomycin A1 or pepstatin Amethyl ester
and E-64D, also led to an increase of both LC3-I and LC3-II accumulation
in FR-treated MCF-7 cells (Fig. 4C). Moreover, we analyzed the
autophagic ﬂux upon co-treatment with rapamycin, chloroquine,
caspase-9 inhibitor, or baﬁlomycin A1 in FR-treated MCF-7 cells using
acridine orange staining. As expected, co-treatment with chloroquine,
caspase-9 inhibitor, or baﬁlomycin A1 inhibited formation of acidic
vesicular organelles (AVOs) in FR-treated MCF-7 cells, but formation of
AVOs (red ﬂuorescence) was observed in rapamycin alone-treated cells
aswell as in FR and rapamycin-treatedMCF-7 cells (Fig. 4D). To conﬁrm
the suppressive effect of caspase-9 in autophagic process, we examined
whether inhibition of caspase-9 had an effect on cathepsin activity,
because cathepsins are lysosomal enzymes and are closely involved in
autophagosomal degradation [30] and also the accumulation of LC3-II
may be related to the activity. Addition of caspase-9 inhibitor efﬁciently
suppressed FR-induced cathepsin activity and chloroquine had a similar
effect, as expected (Fig. 4E). Additionally, we conducted lysosome
staininganalysis usingLysoTrackerRed (LTR),which is a lysosomotropic
ﬂuorescence dye that accumulates within intact acidic lysosomes
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caspase-9 affected vesicular pH in acidic organelles (Fig. 4F) and co-
treatment with caspase-9 inhibitor did not suppress FR-induced GFP-
LC3 puncta formation in stable GFP-LC3 transformants. However,
addition of caspase-9 inhibitor resulted in the emergence of cells with
weak red ﬂuorescence in FR-treated cells. Taken together, these data
suggest that caspase-9maybe correlatedwith acid-dependent activities
of cathepsins and inhibition of caspase-9 may suppress autophagic ﬂux
in FR-treated MCF-7 cells.
3.5. siRNA knockdown of caspase-9 expression sensitizes MCF-7 cells to
FR122047 or sulforaphane-induced cell death
Although the induction of autophagy by sulforaphane treatment
was also conﬁrmed bymarked accumulation of LC3-II, treatment with
etoposide or doxorubicin failed to induce signiﬁcant accumulation of
LC3-II inMCF-7 cells (Fig. 5A). To conﬁrm that the caspase-9 inhibitor-
mediated sensitization of MCF-7 cells to FR-induced cell death was
due to the speciﬁc suppression of caspase-9 activity, we knocked
down the caspase-9 gene expression using caspase-9-speciﬁc siRNA.
MCF-7 cells transfected with the caspase-9 siRNA showed markedlyFig. 5. siRNA knockdown of caspase-9 expression sensitizes MCF-7 cells to FR122047-induce
(Etopo), or 10 μM doxorubicin (Doxo) for 24 h and levels of LC3-I and LC3-II in lysates were
experiments were presented. (B) MCF-7 cells were transfected with control (Con-si) or casp
and 48 h after transfection. Blots representative of the results of three independent experime
FR122047 (FR) or 100 μM sulforaphane (SFN) for a further 24 h, and the proportion of su
independent experiments. *Pb0.05 versus FR or SFN alone. (D) Cathepsin B activity assay
transfection. Values represent the mean±SE of from three independent experiments. *Pb0reduced expression of caspase-9 compared to control (Fig. 5B).
Knockdown of caspase-9 expression resulted in increased suscepti-
bility of cells to FR or sulforaphane-induced cell death (Fig. 5C) and
signiﬁcant suppression of FR- or sulforaphane-induced cathepsin B
activity (Fig. 5D), strongly indicating that caspase-9 may be involved
in speciﬁc drug-induced autophagy.
4. Discussion
Since COXs are highly expressed in tumors and enhance tumori-
genesis, lots of studies have focused on evaluating the possibility of
using COX inhibitors for cancer prevention or treatment. For this reason,
recently, clinical trials are being carried out to investigate the use of COX
inhibitors such as celecoxib as an anticancer agent [4]. Since NSAIDs,
inhibitors of COXs inhibit the enzyme COXs, which convert arachidonic
acid to prostaglandins (PGs), the inhibition of PGs formation accounts
for part of the anticancer effect of NSAIDs. Several studies have shown
that cell growth inhibition caused by treatment with a COX-2 inhibitor
was reversed by addition of PGs [31,32]. However, compelling evidence
suggests that NSAIDs also regulate throughCOXs-independentmechan-
isms. For example, NSAIDs reduced cell survival in COX-deﬁcient celld cell death. (A) Cells were treated with 100 μM sulforaphane (SFN), 400 μM etoposide
analyzed by Western blotting. Blots representative of the results of three independent
ase-9 (Cas9-si) siRNA. Whole-cell lysates were harvested for Western blot analysis 24
nts were presented. (C) At 24 h post-transfection, MCF-7 cells were treated with 30 μM
bdiploid cells was analyzed by FACScan. Values represent the mean±SE from three
was performed after treatment for 12 h with 30 μM FR or 100 μM SFN at 24 h post-
.05 versus the control (DMSO), **Pb0.05 versus FR or SFN alone.
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cellular pathway, independent of COX inhibition [35]. In the present
study, we could ﬁnd that the NSAID FR122047 induces COX activity-
independent cell death in breast cancer MCF-7 cells (data not shown).
After FR treatment, we could observe an alteration of mitochon-
drial membrane potential, indicative of a well-established intrinsic
apoptotic pathway (Fig. 1G), as well as recruitment of caspase-8 into
FADD, which correlates with the extrinsic apoptotic pathway (Fig. S2).
FR treatment also resulted in induction of Bid cleavage into truncated
form (tBid) (Fig. 1E), an increase in the Bax/Bcl-2 ratio (Fig. 1E), and
signiﬁcant release of mitochondrial cytochrome c (Fig. 1H). Based on
our observations, we could propose the involvement of caspase-9 in
the mechanism of FR-induced cell death and actually detected
caspase-9 activation (Fig. 1I). However, treatment of the caspase-9
inhibitor z-LEHD-FMK was unable to block but it rather enhanced FR-
induced cell death (Fig. 2A), although the inhibitor suppressed the
cleavage of PARP and caspase-7 (Fig. 2C). Furthermore, siRNA-
mediated knockdown of caspase-9 expression in MCF-7 cells caused
increased susceptibility of cells to FR-induced cell death (Fig. 5C),
consistent with the results obtained with caspase-9 inhibitor.
These data led us to hypothesize that caspase-9might be involved in
another pathway speciﬁcally regulating the typical apoptotic signaling
pathway. We could observe hallmarks of autophagy, e.g., autophago-
somes and autophagolysosomes, in FR-treatedMCF-7 cells.More recent
studies suggest that autophagy can be either a process that contributes
to cell death or a defense mechanism. For example, inhibition of
autophagy blocked TNFα-induced apoptosis in human T-lymphoblastic
leukaemic cells [36], while autophagy protected cells from sulfora-
phane-induced apoptosis in human prostate cancer cells [23]. In our
study, autophagywas shown to be cytoprotective as co-treatment of the
cells with rapamycin, a well-known inducer of autophagy [27],
suppressed FR-induced cell death in MCF-7 cells (Fig. 4A).
We examined whether the caspase-9 inhibitor had any effect on the
autophagic process and could ﬁnd compelling experimental evidence
that treatmentwith the inhibitor suppresses the autophagic event. First
of all, we originally could ﬁnd that inhibition of caspase-9 blocks the FR-
induced increase in activity of cathepsin. Several previous studies have
reported that a relationshipmay exist between caspase-9 activation and
cathepsin activity. Gyrd-Hansen et al. reported that caspase-8-activatedFig. 6. Treatment with FR122047 triggers the activation of both caspase-9 and caspase-8 in M
FR-induced cell death. In contrast, inhibition of caspase-9 sensitizes MCF-7 cells to FR-induce
suppression of cytoprotective autophagy during FR-induced cell death. Although treatment
death, it does not lead to signiﬁcant autophagy. Cell death induced by these drugs is signiﬁca
apoptotic pathway may be important in the cell death induced by these drugs.caspase-9 triggers lysosomal membrane permeabilization, leading to
cell death [37]. They also showed that caspase-9-deﬁcient cells exhibit
decreased cathepsin activity in lysosomal cell death compared to
parental cells. However, they did not provide any data showing the
involvement of caspase-9 activity in autophagic process. In our study, to
conﬁrm the suppressive effect of caspase-9 in autophagic process, we
introduced the acridine orange staining and lysosome staining analyses.
Our data showed that inhibition of caspase-9 affected vesicular pH in
acidic organelles (Fig. 4F) and co-treatmentwith caspase-9 inhibitor did
not suppress FR-induced GFP-LC3 puncta formation in stable GFP-LC3
transformants. However, addition of caspase-9 inhibitor resulted in the
emergence of cells with weak red ﬂuorescence in FR-treated cells,
indicating that inhibition of caspase-9 evidently inﬂuenced vesicular pH
in acidic lysosomes. These results strongly suggest that caspase-9 may
be involved in regulation of lysosomal pHandacid-dependent cathepsin
activities. Moreover, co-treatment of FR and caspase-9 inhibitor
signiﬁcantly reduced the quantity of acridine orange-positive vesicles
compared to FR alone treatment (Fig. 4D), conﬁrming that the
autophagosomes produced by FR undergo the maturation process
with the fusion with lysosomes. Indeed, in the caspase-9 inhibitor-
treated cells, LC3-II levels remain elevateddespite of amarked reduction
of acidic vesicles, indicating that the earlier stages of autophagy prior to
lysosomal fusion were not affected by caspase-9 inhibitor. In contrast,
caspase-8 inhibitor had no effect on both LC3-II accumulation and
caspase-9 activation in FR-treatedMCF-7 cells, even though it inhibited
caspase-8-dependent cleavage of BID (Fig. S3), implying that caspase-
8 activation seems to be not directly involved in FR-induced autophagy
ofMCF-7 cells. These data originally suggest that inhibition of caspase-9
may block the autophagicﬂux and enhance cell death due to blockage of
cytoprotective autophagy (Fig. 6).
We then askedwhether enhancement of cell death inMCF-7 cells by
co-treatment with caspase-9 inhibitor is limited to FR. Previous studies
had shown that etoposide and doxorubicin induce cell death by
activation of caspase-9 [38]. As expected, caspase-9 inhibition was
found to have an inhibitory effect on etoposide- and doxorubicin-
induced cell death in MCF-7cells (Fig. 2E). Moreover, caspase-
8 inhibition had no effect on doxorubicin-induced cell death in the
MCF-7 cells (Fig. S4). Interestingly, neither etoposide nor doxorubicin
induced signiﬁcant autophagic event such as conversion of LC3-I to LC3-CF-7 cells. Blockade of caspase-8-mediated apoptosis results in apparent suppression of
d cell death. It seems that the cell death enhanced by caspase-9 inhibitor correlates with
of anticancer drugs such as etoposide or doxorubicin results in apparent apoptotic cell
ntly blocked by addition of caspase-9 inhibitor. It appears that the caspase-9-dependent
89H.-S. Jeong et al. / Biochimica et Biophysica Acta 1813 (2011) 80–90II in MCF-7 cells (Fig. 5A). These data suggest the possibility that
caspase-9 may have autophagy-involved another function in drug-
induced cell death accompanied by signiﬁcant autophagy. Further
experiments are required to analytically examine this possibility and
currently underway.
In recent years, there has been increasing evidence that caspase
inhibition by speciﬁc caspase inhibitor can induce events independent of
blocking cell death or apoptosis. Loss of caspase-8 has been reported to
promote dissemination of neuroblastoma cells [39], and inhibition of
caspase-3 activity resulted in attenuated neurite extension and cellular
remodeling during differentiation [40]. Treatment of pan-caspase
inhibitor, z-VAD-FMK, has been shown to induce necrotic cell death in
L929murineﬁbrosarcoma cells [41].Moreover, treatment of a caspase-9
inhibitorwas reported to augment stress-induced apoptosis in B-lineage
cells [15], enhance the generation of ROS, and induce necrosis in RAW
264 macrophage cells infected with Mycobacterium tuberculosis [14].
These ﬁndings raise the possibility that there may be more diverse
functions of caspases than thought.
In conclusion, our data show that treatment of breast cancer MCF-7
cells with the NSAID FR122047 led to caspase-mediated apoptosis and
simultaneously stimulated cytoprotective autophagy.We could observe
hallmarks of intrinsic pathway-mediated apoptosis, but inhibition of
caspase-9 enhanced FR-induced cell death by blocking autophagy. Our
data provide new insights into the understanding of the function of
caspase-9 during the process of cytoprotective autophagy.
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